Skip to Content


Ed Silverman, quoting Rachel Sachs (Academic Fellow Alumna)
STAT
April 24, 2018

Read the Full Article

From the article:

In a blow to the pharmaceutical industry, the U.S. Supreme Court ruled that a controversial procedure for reviewing patent disputes does not violate the constitutional rights of patent holders.

Known as inter partes reviews, these are heard before a U.S. Patent and Trademark Office appeals board, not a court, and anger drug makers because they are easier and faster to pursue than typical patent lawsuits. Drug companies have argued patents are private property that may be revoked only by a federal court and the review process violates a constitutional right to be heard by a court and jury.

Read more here!

Read the Full Article

Tags

health care finance   pharmaceuticals   rachel sachs   regulation